EGF
Epidermal Growth Factor (EGF)[edit | edit source]
Epidermal Growth Factor (EGF) is a protein that stimulates cell growth, proliferation, and differentiation by binding to its receptor, EGFR. It is a critical component in the regulation of cell growth and has significant implications in both normal physiological processes and pathological conditions such as cancer.
History[edit | edit source]
EGF was first discovered by Stanley Cohen in the 1960s, for which he was awarded the Nobel Prize in Physiology or Medicine in 1986, shared with Rita Levi-Montalcini. Cohen's work laid the foundation for understanding how cells communicate and respond to external signals.
Structure[edit | edit source]
EGF is a small protein composed of 53 amino acids. It is characterized by three disulfide bridges that stabilize its structure. The protein is initially synthesized as a larger precursor molecule, which is then cleaved to release the active form of EGF.
Mechanism of Action[edit | edit source]
EGF exerts its effects by binding to the EGFR, a transmembrane receptor with intrinsic tyrosine kinase activity. Upon binding, EGFR undergoes dimerization and autophosphorylation, triggering a cascade of downstream signaling pathways, including the MAPK/ERK pathway, PI3K/AKT pathway, and JAK/STAT pathway. These pathways lead to various cellular responses such as proliferation, differentiation, and survival.
Biological Functions[edit | edit source]
EGF plays a crucial role in:
- Wound healing: EGF promotes the proliferation and migration of keratinocytes and fibroblasts, accelerating the healing process.
- Embryonic development: It is involved in the development of various tissues and organs.
- Gastrointestinal tract: EGF is present in saliva and plays a role in maintaining the integrity of the gastrointestinal mucosa.
Clinical Significance[edit | edit source]
Cancer[edit | edit source]
Overexpression or mutation of EGFR is implicated in various cancers, including non-small cell lung cancer, colorectal cancer, and glioblastoma. Targeted therapies, such as EGFR inhibitors (e.g., gefitinib, erlotinib), have been developed to block the aberrant signaling in these cancers.
Therapeutic Applications[edit | edit source]
EGF is used in topical formulations to enhance wound healing and skin regeneration. It is also being investigated for its potential in treating neurodegenerative diseases and other conditions.
Research and Developments[edit | edit source]
Ongoing research is focused on understanding the complex interactions between EGF and its receptor, as well as developing novel therapeutic agents that can modulate this pathway more effectively.
See Also[edit | edit source]
References[edit | edit source]
- Cohen, S. (1962). "Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the newborn animal." Journal of Biological Chemistry.
- Carpenter, G., & Cohen, S. (1990). "Epidermal growth factor." Annual Review of Biochemistry.
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD